Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482501 | 0.95 | CCR5 (0.84) | CCR5KCNH2 | |
| SCHEMBL3664308 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL4461717 | 0.91 | CCR5 (1.00) | CCR5KCNH2 | |
| SCHEMBL18841093 | 0.91 | CCR5 (1.00) | CCR5KCNH2 | |
| SCHEMBL4485065 | 0.91 | CCR5 (0.88) | CCR5KCNH2 | |
| SCHEMBL3626623 | 0.90 | CCR5 (0.85) | CCR5KCNH2 | |
| SCHEMBL13604581 | 0.90 | CCR5 (0.87) | CCR5KCNH2 | |
| SCHEMBL4498265 | 0.90 | CCR5 (0.87) | CCR5KCNH2 | |
| SCHEMBL4471153 | 0.90 | CCR5 (0.87) | CCR5KCNH2 | |
| SCHEMBL3630706 | 0.90 | CCR5 (0.87) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | claimed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | claimed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | CCR5 1/4885KCNH2 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.